Norathyriol, a small molecule targeting circPETH-147aa, reverses these effects, enhancing anti-PD1 therapy and restoring CD8+ T-cell activity, highlighting its potential in overcoming ICB resistance in HCC (84). This evidence concerns the gene CD8A and hepatocellular carcinoma.